Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a 28-day, placebo controlled clinical study assessing the safety, tolerability
anti-inflammatory effect and pharmacokinetics of SB681323 in patients with COPD (Chronic
Obstructive Pulmonary Disease).